Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Comment by Hideawayon May 08, 2021 12:43pm
155 Views
Post# 33159951

RE:RE:RE:Inherent Value

RE:RE:RE:Inherent ValueGourt,great post with you're insights so clearly stated.Hope you keep posting.
As a longtime investor in ATE,we are finally starting to experience the potential longs have hoped to see.Still a way to go but a good commencement.
As an aside,my son is an anesthesiologist and does some pain management.He did not invest in ATE although he is keenly aware as to the need for new drugs to replace nsaids and opioids.He feels it is too early in the Company's development and pointed out the hazards of investing in early stage biotechs.My past experiences with juniors bears out the need for caution.However, I was impressed by my DD into ATE and thus became an investor a few year's ago. I have not had a chance to inform my son of these latest developments,but will do so soon.Hope he might now participate in what could be a very rewarding experience.



<< Previous
Bullboard Posts
Next >>